Cost

Cost Per Dose in Cell and Gene Therapy: Building a Defensible Quote

A money-first breakdown of cost per dose in cell and gene therapy: materials, cleanroom time, labor, scrap, and the overhead that estimators forget.

Cost per dose in cell and gene therapy is dominated by fixed and batch-level costs, not per-unit material, which flips the intuition estimators bring from high-volume manufacturing. For an autologous product, a batch is often a single patient dose, so every batch-level cost lands on one unit. Fully loaded cost per dose commonly runs 100,000 to 500,000 dollars, and allogeneic products spread batch cost across hundreds of doses to reach 15,000 to 60,000 dollars. The estimating job is allocating batch cost to the right dose count, which is why your assumed doses-per-batch is the single most sensitive line in any quote.

Single-use consumables are the largest visible material line. A closed-system manufacturing kit with tubing sets, bags, filters, and a bioreactor vessel runs 8,000 to 25,000 dollars per batch, and viral vector for a transduction step can add 20,000 to 100,000 dollars depending on multiplicity of infection and vector titer. Use the Single-Use Kit Cost calculator to build this from the component bill rather than a lump percentage, because a design change that adds one sterile connector at 120 dollars across 4 batches a week is 25,000 dollars a year hiding in a rounding error.

Cleanroom time is where hidden money sits. A Grade B suite carries a fully burdened cost of 400 to 900 dollars per hour once you load HVAC, gowning consumables, environmental monitoring, and depreciation. A 12 day autologous batch that occupies a suite for 288 hours therefore absorbs 115,000 to 260,000 dollars of facility cost before you touch labor or materials. The GMP Cleanroom Utilization Cost calculator converts suite occupancy into dollars, and it exposes the biggest lever in the model: idle suite time between batches, where a suite at 45 percent utilization doubles the facility cost each dose carries versus 90 percent.

Labor is expensive because of ratios, not wages. GMP manufacturing typically runs 2 to 4 operators per suite with dual-operator verification for chain-of-identity and open steps, plus a QA-on-the-floor presence. Loaded operator cost of 65 to 110 dollars per hour times 3 operators times 288 suite hours is 56,000 to 95,000 dollars of direct labor per autologous batch. Add QC analyst time for release testing at roughly 40 to 80 hours per batch. The Chain-of-Identity Equipment Workload calculator helps confirm you are not staffing double verification at every step when a subset actually requires it.

Scrap is not a percentage in this category; it is a full batch loss, and it is huge. A failed autologous batch means a patient dose is gone, and the Cell Therapy Batch Failure Cost calculator adds direct material, consumed cleanroom time, labor, and the downstream cost of a re-collection or a missed treatment window. At a 10 percent batch failure rate, every successful dose must carry roughly 1 / 0.9 = 1.11 times its own cost to cover the losers, so a 200,000 dollar nominal cost becomes 222,000 dollars effective. Quote against your trailing failure rate, not your target.

Validation and documentation are real per-dose costs early in a product's life. Process validation typically requires 3 consecutive conformance batches, and the Validation Batch Cost calculator captures that those batches often cannot be sold, so their full cost, frequently 600,000 to 1.5 million dollars combined, amortizes across projected commercial volume. On a 2,000 dose first-year forecast that is 300 to 750 dollars per dose. The GMP Documentation Burden Score calculator quantifies batch record and deviation review effort, which for complex products adds 20 to 60 QA hours per batch that estimators routinely leave out of the quote entirely.

Build the quote bottom up and label every assumption. Start with doses per batch from real yield data, sum consumables, cleanroom hours times burdened rate, direct and QA labor, then gross up for batch failure rate and amortized validation. Add overhead for QC release, cold-chain logistics, and cryostorage at 50 to 150 dollars per vial-year. Present a nominal case and a downside case at your 10th percentile yield and trailing failure rate. Quotes go wrong when they assume best-ever yield, 100 percent suite utilization, and zero failures at once, a stack of optimism that can understate true cost per dose by 40 percent or more.

Published 2026-07-02.